CD4 and neoplasm: While cDC1 primarily drives CD8+ cytotoxic T-lymphocytes (CTL) responses and cDC2 activates CD4+ T-lymphocytes within the TME, inadequate DC recruitment under tumor growth conditions hampers anti-tumor immunity [4, 6].